Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus (NASDAQ: EOLS) has granted equity incentives to 16 newly hired non-executive employees in May 2025. The compensation package includes 12,706 non-qualified stock options with an exercise price of $9.98 per share and 40,576 restricted stock units (RSUs). The stock options have a 10-year term and vest over 4 years, with 25% vesting annually. Similarly, the RSUs vest 25% each year. These awards were approved under the Evolus 2023 Inducement Incentive Plan, with a grant date of May 12, 2025, and vesting commencement date of May 7, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Evolus (NASDAQ: EOLS) reported strong Q1 2025 financial results with global net revenue of $68.5 million, up 15.5% year-over-year. The company posted a GAAP operating loss of $15.2 million and a non-GAAP operating loss of $5.5 million. Despite operating in a slower market, Evolus gained meaningful market share and successfully launched Evolysse™ in Q2.
Key highlights include: over 16,000 total customers with a 70% reorder rate, Evolus Rewards™ program growing to over 1.1 million members (39% YoY increase), and record-high quarterly redemptions exceeding 220,000. The company reaffirmed its 2025 revenue guidance of $345-355 million, with Evolysse™ and Estyme® expected to contribute 8-10% of total revenue.
Looking ahead, Evolus projects reaching $700 million in revenue by 2028 (27% CAGR from 2024) and achieving non-GAAP operating income margins of at least 20% by 2028.
Evolus (NASDAQ: EOLS) has successfully refinanced its credit facility, replacing the existing $125 million agreement with a new $250 million facility managed by Pharmakon Advisors. The new facility features a 350 basis points reduction in borrowing costs, with interest at 3-month SOFR plus 5.00% per annum and a five-year maturity. The structure includes a $150 million initial draw and two additional optional tranches of $50 million each available through December 2026.
Key improvements include conversion from amortizing to bullet maturity payment, reduced prepayment fees, and increased financial flexibility. The refinancing eliminates the need for principal payments in 2026 and provides enhanced working capital flexibility to support commercial momentum and strategic initiatives.
Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025, after U.S. market close.
Management will host a conference call and webcast at 4:30 p.m. ET the same day, including a Q&A session. Participants can join via phone at (800) 579-2543 (U.S.) or (785) 424-1789 (international), or through the live webcast on the company's Investor Relations webpage.
Evolus (NASDAQ: EOLS) has announced the granting of 30,579 restricted stock units (RSUs) to 13 newly hired non-executive employees under its 2023 Inducement Incentive Plan. The grants were approved by the company's compensation committee as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs have a grant date and vesting commencement date of April 7, 2025, with 25% vesting on each annual anniversary. The awards are contingent upon continuous employment through each vesting date and are subject to the terms of the 2023 Inducement Incentive Plan and respective agreements.
Evolus (NASDAQ: EOLS) has announced the commercial launch of Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, scheduled for April 18th. The launch includes an early experience program with over 1,000 key accounts and a national Evolus Academy webcast.
The Evolysse™ collection represents the company's second commercial aesthetics product after Jeuveau®, which has achieved over 14% U.S. market share and penetration in 50% of aesthetic clinics. The new products utilize innovative Cold-X™ technology for treating facial wrinkles and folds.
In clinical trials against Restylane®-L, both Evolysse™ products demonstrated statistical superiority at the 6-month primary endpoint. Evolysse™ Form showed significant differences throughout the 12-month study period, while Evolysse™ Smooth showed significant differences at 6 and 9 months, despite using 20% less product than Restylane®-L.